Pliant Therapeutics
PLRX
160 hedge funds and large institutions have $853M invested in Pliant Therapeutics in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 55 increasing their positions, 43 reducing their positions, and 13 closing their positions.
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
28% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 43
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
18% more capital invested
Capital invested by funds: $725M → $853M (+$127M)
6% more funds holding
Funds holding: 151 → 160 (+9)
1.99% more ownership
Funds ownership: 104.43% → 106.42% (+2%)
88% less call options, than puts
Call options by funds: $1.26M | Put options by funds: $10.7M
Top Buyers
Top Sellers
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$12.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$11.7M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$6.92M |
| 4 |
Barclays
London,
United Kingdom
|
-$4.36M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$4.12M |
PLRX Hedge Fund Activity: Q4 2024 in Review
160 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q4 2024, worth a combined $853M — up 18% from $725M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PLRX positions and 13 closed out — a net gain of 10 holders — while 55 added to existing stakes and 43 trimmed.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $18M. The largest seller was First Light Asset Management, cutting an estimated $12.2M.
- 160 institutional investors held Pliant Therapeutics (PLRX) as of Q4 2024, up from 151 in Q3 2024.
- Funds reported $853M of Pliant Therapeutics stock for Q4 2024, up 18% quarter-over-quarter.
- 23 funds opened new Pliant Therapeutics positions in Q4 2024 and 13 closed out, a net change of +10 holders.
- The largest Pliant Therapeutics buyer in Q4 2024 was Silverarc Capital Management, an estimated $18M added.
- The largest Pliant Therapeutics seller in Q4 2024 was First Light Asset Management, an estimated $12.2M sold.
Based on aggregated 13F filings for Q4 2024.